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Abstract
Background—Contemporary data on patterns of antiretroviral therapy (ART) use in the U.S. are
needed to inform efforts to improve the HIV care cascade.
Methods—We conducted a cross-sectional study of patients in the Centers for AIDS Research
Network of Integrated Clinical Systems cohort who were in HIV care in 2010 to assess ART use
and outcomes, stratified by nadir CD4 count (≤350, 351-500, or >500 cells/mm3), demographics,
psychiatric diagnoses, substance use, and engagement in continuous care (≥2 visits ≥3 months
apart in 2010).
Results—Of 8633 patients at 7 sites who had ≥1 medical visit and ≥1 viral load (VL) in 2010,
94% had ever initiated ART, 89% were on ART, and 70% had an undetectable VL at the end of
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2010. Fifty percent of ART-naïve patients had nadir CD4 counts >500 cells/mm3, but this group
composed just 3% of the total population. Among patients who were ART-naïve at the time of
cohort entry (N=4637), both ART initiation and viral suppression were strongly associated with
nadir CD4 count. Comparing 2009 and 2010, the percentages of patients with viral suppression
among those with nadir CD4 counts 351-500 and >500 cells/mm3 were 44% vs. 57% and 25% vs.
33%, respectively. Engagement in care was the only factor consistently associated with ART use
and viral suppression across nadir CD4 count strata.
Conclusions—Our findings suggest that ART use and viral suppression among persons in HIV
care may be more common than estimated in some prior studies and increased from 2009 to 2010.
Keywords
Antiretroviral Therapy, Highly Active; HIV Infections/drug therapy; HIV Infections/prevention &
control; Patient Acceptance of Health Care/statistics & numerical data; United States
INTRODUCTION
Suppression of the plasma HIV RNA level is a key goal of medical care for persons living
with HIV/AIDS (PLWHA) and is increasingly a focus of public health efforts to prevent
HIV transmission.1 National estimates suggest that only 19-28% of PLWHA in the U.S have
achieved viral suppression2-5 due to compounding breakdowns at each step in the HIV care
cascade. However, such estimates are imprecise, reflecting incomplete nationwide
surveillance data on viral suppression and the inability of surveillance systems to ascertain
ART use. While public health authorities can estimate levels of viral suppression using
laboratory reporting of HIV RNA [viral load (VL)] test results, these estimates are limited in
many areas by incomplete reporting and by uncertainty about which persons determined to
be HIV-infected in a surveillance area continue to reside in that area.6 The Centers for
Disease Control and Prevention’s (CDC) Medical Monitoring Project (MMP) estimates
ART use with probability-based sampling of HIV care facilities and patients in care during
the first four months of the year, but to date, MMP data have been limited by incomplete
provider and patient participation.7
In addition to the importance of contemporary data on ART use and viral suppression, a
clearer understanding of how ART uptake varies among PLWHA in different nadir CD4
count groups is important for monitoring the effect of changes in treatment guidelines and
the impact of reductions in state AIDS Drug Assistance Programs, identifying disparities in
treatment access, and projecting resources required to expand ART use among PLWHA in
the U.S. Little is known about the size and composition of the population of persons in HIV
care who have nadir CD4 counts >500 cells/mm3, a group of particular interest in the
context of revised guidelines for ART initiation and increasing optimism about the potential
for “test and treat” strategies to decrease the size of the HIV epidemic. Furthermore,
contemporary estimates of ART use and viral suppression among persons in HIV care can
aid studies to assess the impact of expanded health insurance coverage among PLWHA in
the U.S. under the Affordable Care Act.
The primary goal of this study was to estimate the proportion of persons who have initiated
ART, are on continuing ART, and have viral suppression in a nationally distributed cohort
of persons in HIV care in the U.S. Our secondary objectives were to compare ART use and
viral suppression by nadir CD4 count group and to determine factors associated with being
ART-naive, discontinuing ART, and/or having detectable viremia despite continuing ART
use, stratified by nadir CD4 count.
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We conducted a cross-sectional study of patients in the Centers for AIDS Research (CFAR)
Network of Integrated Clinical Systems (CNICS) cohort, which includes over 25,000 HIV-
infected adults in care dating back to 1995 at eight university-affiliated CFARs. The
methodology and characteristics of the CNICS cohort are described in detail elsewhere.8
Briefly, CNICS is a dynamic observational cohort with approximately 1400 new patients
enrolling and 13% of existing patients leaving care each year. The CNICS data repository
systematically captures information from electronic health records (EHRs) and pharmacy
systems at each CNICS site. Validation of data occurs in three phases: at the individual sites
prior to data transmission, at the time of data submission to the Data Management Core prior
to insertion into the central repository, and through the use of automated validation
procedures at the time of data integration. Data then undergo an extensive set of quality
assurance procedures and data quality issues are reported to CNICS sites to investigate and
correct.
Our objective was to assess historical and current ART use among patients in care at the end
of 2010, one year after the publication of HIV treatment guidelines recommending ART
initiation before progression of the CD4 count to <500 cells/mm3. The study population
included patients who were in care (≥ 1 medical visit) and had ≥ 1 VL measurement in 2010.
In order to focus on a population in which clinicians and patients had sufficient time to carry
out treatment decisions in response to CD4 counts <500 cells/mm3, we limited the study
population to patients who entered the cohort ≥9 months prior to the end of 2010. We
excluded patients who entered care prior to the combination ART era, defined as before
January 1, 1997 (N=1311); women who appeared to be receiving ART for perinatal
treatment at the time of their most recent regimen (N=20); and patients from one CNICS
clinic site due to incomplete data (N=914).
We analyzed the proportion of patients ever on ART, on continuing ART, and with viral
suppression at the end of 2010. We classified subjects as “ever on ART” if they had initiated
ART on or before December 31, 2010 and as “on continuing ART” if they had initiated
ART and had no documentation of discontinuing all ART as of December 31, 2010. The
latter group included patients who discontinued then restarted ART as long as they
continued a regimen through the end of 2010. ART initiation and cessation dates defined by
the treating provider in the EHR and in pharmacy prescription fill/refill data were validated
at the individual sites and centrally through chart review and applications to monitor data
quality. During our analysis the Data Management Core sent lists of patients who had
undetectable viral loads but no corresponding ART data to each CNICS site for
investigation. The sites responded with corrected ART data or confirmation of elite
controller status for each case.
For analysis of viral suppression, we identified the last recorded VL for each patient and
defined suppression as any result below the level of quantitation of the assay. We focused on
undetectable VL as the primary outcome for viral suppression because it is the primary
clinical goal of ART and the Institute of Medicine (IOM) recommended indicator.9 We
separately report the proportion of patients with VL ≤200 copies/mL to facilitate comparison
with other reports.4, 5, 10 We did not exclude patients who had viral suppression in the
absence of ART initiation from this analysis because our goal was to assess viral
suppression in the entire study population, regardless of the underlying mechanism of
suppression.
We conducted a subset analysis stratifying each outcome (ever on ART, continuing ART,
and viral suppression) by nadir CD4 count. We grouped subjects by nadir CD4 count ≤350,
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351-500, or >500 cells/mm3 based on the relevance of these categories to U.S. HIV
treatment guidelines for ART initiation. We limited analysis of nadir CD4 count to patients
who were ART-naïve at the time of entry into the CNICS cohort since pretreatment CD4
counts are not uniformly available in patients who were treatment experienced at entry. We
identified the nadir CD4 count for each patient as of March 31, 2010. We conducted a repeat
cross-sectional analysis in order to compare patterns of ART use and viral suppression in
2009 and 2010, using the same methods as those described above to assess the outcomes at
the end of 2009 among patients who had entered the cohort prior to March 31, 2009.
For bivariate comparisons of ART use and viral suppression by patient subpopulation, we
used Pearson’s chi-square tests. We selected independent variables a priori, based on
previous demonstrations of association with ART initiation, adherence and/or viral
suppression,11-14 including age, sex, race/ethnicity, HIV risk group, engagement in HIV
care, psychiatric disorders and substance abuse. We categorized HIV risk group as men who
have sex with men (MSM) [including injection drug using (IDU) MSM], IDU, non-IDU
heterosexual, and other. We defined engagement in continuous care as ≥ 2 visits ≥ 3 months
apart in 2010, the measure recommended by IOM9 and the U.S. National HIV/AIDS
Strategy.15 We analyzed psychiatric and substance use disorders diagnosed by treating
providers. These data are not available uniformly from all CNICS sites, and we limited
analysis of these variables to patients from reporting sites. We used the methodology
validated by Tegger and colleagues16 to categorize psychiatric comorbidities and substance
use into separate, mutually exclusive, hierarchical groups: (1) psychotic disorder, bipolar
disorder, and /or personality disorders with or without depression and anxiety, (2)
depression and/or anxiety only, (3) no mental illness. We categorized substance use into five
mutually exclusive, hierarchical groups: (1) opiates with or without other drugs, (2)
amphetamines with or without other drugs, (3) cocaine with or without alcohol, (4) alcohol
only, or (5) no substance use.16 Patients at CNICS sites that report these data who did not
have a diagnosis were classified as having “none of the above” diagnoses. We were unable
to distinguish treated from untreated psychiatric disorders or active from past substance use.
We used Poisson regression clustered by clinic site for multivariate analysis of three
outcome measures, stratified by nadir CD4 count. For these models we defined the outcomes
as “failure” isolated to individual steps in the care cascade: ART non-initiation, ART
discontinuation, and detectable viremia despite continuing ART use. Poisson regression
allows for calculation of estimated relative risks instead of odds ratios in cohort data.17 We
estimated prevalence ratios (PR) of each outcome at the end of 2010. Clustered analysis
adjusts for correlation between results from individual sites, thereby accounting for
unmeasured factors associated with potentially different ART prescribing practices. We
constructed a model for each of the three outcome measures for each of the nadir CD4
groups. Our initial models included all of the independent variables we defined a priori,
except for psychiatric and substance abuse since not all sites reported this information, and
we retained all variables in the final model. We then explored the potential effect of length
of time in care on ART initiation, and because this was significantly associated with ART
initiation in one nadir CD4 group, the final models include adjustment for years in care at a
CNICS site. We used Stata 10.1 for all analyses (StataCorp, TX). Institutional review boards
(IRB) at each university approved data collection procedures, and the University of
Washington IRB judged this analysis to be exempt from review due to the use of de-
identified data.
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ART Use and Outcomes among Patients in Care in 2010
The study population included 8633 persons from seven CNICS sites (range 720 −1,735
patients per site) who met inclusion criteria for active HIV medical care in 2010 (Figure 1).
As of December 31, 2010, these patients had been in care at CNICS sites for a median of 60
months [interquartile range (IQR): 30-100 months]. The inclusion criteria of ≥1 visit and ≥1
VL in 2010 excluded 1312 persons (13%) compared to the population of patients with ≥1
visit and ≥1 VL anytime in either 2009 or 2010 (N=9945).
At the end of 2010, 94% of patients had ever been on ART (range: 92-95% across sites),
89% were on continuing ART (range: 88-91%), and 70% had viral suppression (range:
56-85%) (Table 1). By the less restrictive definition of VL ≤200 copies/mL, 79% (range:
71-86%) had viral suppression. Restricting the analysis to patients who had been on ART ≥6
months, the prevalence of viral suppression was similar in patients on ART <1 year (76%)
compared to >1 year (78%; p=0.45). The distribution of the 555 patients who remained
ART-naïve at the end of 2010 by nadir CD4 count was as follows: 102 (18%) ≤350 cells/
mm3, 177 (32%) 351-500 cells/mm3, and 276 (50%) >500 cells/mm3. Approximately 1% of
the study population (N=70) had undetectable VL in the absence of documented ART
initiation, of whom 16 (23%) had a nadir CD4 count ≤350 cells/mm3, 18 (26%) 351-500
cells/mm3, and 36 (51%) >500 cells/mm3.
In bivariate analysis, viral suppression was less common among women compared to men
(p<0.001); patients <50 compared to >50 years of age (p<0.001 for all comparisons); non-
Hispanic blacks compared to non-Hispanic whites (p<0.001); and patients not engaged
compared to those engaged in continuous care (p<0.001). Viral suppression was more
common in MSM than heterosexuals and IDU (p<0.001). Comparing patient subgroups,
differences in the proportion of patients who had initiated ART were generally smaller than
differences in the proportion of patients with viral suppression. For example, 92% of non-
Hispanic blacks and 94% of non-Hispanic whites had initiated ART, but only 62% of non-
Hispanic blacks had viral suppression compared to 73% of non-Hispanic whites.
ART Use and Outcomes in Patients who were ART-naïve at the Time of Entry into Care
Table 2 shows ART status and viral suppression, stratified by nadir CD4 count, in the 4637
patients who were ART-naïve at the time of entry into care at a CNICS site. These patients
had been in care at CNICS sites for a median of 60 (IQR: 31-99) months. Initial CD4 counts
after entry to care were ≤350 cells/mm3 in 49%, 350-500 cells/mm3 in 22%, and >500 cells/
mm3 in 28% of patients. At the end of 2010, 88% of patients had initiated ART, 85% were
on continuing ART, and 67% had viral suppression (76% had VL ≤ 200 copies/mL). More
patients with nadir CD4 counts ≤ 350 cells/mm3 had initiated ART and were on continuing
ART (97% and 94%, respectively) compared to patients with nadir CD4 counts 351-500
cells/mm3 (73% and 70%, respectively) and >500 cells/mm3 (38% and 36%, respectively)
(p<0.001 for all comparisons). Similarly, the proportion of patients with viral suppression,
on or off ART, varied by nadir CD4 group (≤350 cells/mm3: 73%; 351-500 cells/mm3: 57%;
>500 cells/mm3: 33%; p<0.001). The association of lower nadir CD4 count with higher
levels of ART use and viral suppression was evident across all subgroups presented in Table
2. Among patients on ART for ≥6 months, there was a trend toward higher rates of
suppression in patients who initiated ART with higher CD4 counts [(≤350 cells/mm3, 79%;
351-500 cells/mm3, 82%; >500 cells/mm3, 86% (p=0.095)].
Of 4265 patients who met inclusion criteria for analysis of ART initiation at the end of 2009,
85% had ever been on ART, 80% were on continuing ART, and 65% had viral suppression.
The proportions of patients who had ever initiated ART, were on ART and with viral
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suppression were higher among those with nadir CD4 counts of 351-500 and >500 cells/
mm3 in 2010 compared to 2009 (Table 2).
Engagement in Continuous Care
Overall, approximately 16% of the entire study population (N=8633) and of the patients who
were ART-naïve at cohort entry (N=4637) were not engaged in continuous care. Among
those ART-naïve at cohort entry, non-engagement was more common among those with
higher nadir CD4 counts (≤350 cells/mm3: 16%; 351-500 cells/mm3: 18%; >500 cells/mm3:
21%; p=0.02). Adjusting for nadir CD4 count, engagement in care was the single factor
most strongly and consistently associated with ART use and viral suppression. Younger age
was associated with poorer care engagement [age 18-29: PR 0.94 (95% CI: 0.91 – 0.97); age
30-39: PR 0.96 (95% CI: 0.94 – 0.97) compared to patients >50 years of age], as was non-
Hispanic black race [PR 0.97 (95% CI: 0.95 – 0.996)], controlling for nadir CD4 count.
Factors Associated with Failure to Initiate ART, Continue ART, and Achieve Viral
Suppression
Tables 3, 4, and the online supplemental table 5 present the results of multivariate analyses
assessing the association of independent variables with ART non-initiation, ART
discontinuation among patients who initiated ART, and detectable viremia in patients on
continuing ART, stratified by nadir CD4 count, among patients who were ART-naïve at the
time of entry to care (N=4637). Failure to engage in continuous care was consistently
associated with viremia across all nadir CD4 count groups and with lower levels of ART
initiation and ongoing use in patients with nadir CD4 counts ≤500 cells/mm3. Otherwise,
associations were heterogeneous across nadir CD4 groups. In the population with the
strongest indication for treatment (CD4 counts <350 cells/mm3), failure at each step was
generally higher among young people and African Americans though not all PR associating
these factors with failures were significant.
DISCUSSION
We found that, among patients in HIV care at one of seven CNICS sites during 2010, 94%
had ever initiated ART, 89% were on continuing ART, and 70% had viral suppression at the
end of 2010. Treatment initiation increased from 2009 to 2010 in patients with a nadir CD4
count >350 cells/mm3, including those with a nadir CD4 count >500 cells/mm3. This
demonstrates a movement toward earlier ART initiation in practice likely due, in part, to
revised treatment guidelines in 2009. ART-naïve patients with a nadir CD4 count >500
cells/mm3 accounted for just 3% of the total population, indicating that the most recent
revision of U.S. HIV/AIDS treatment guidelines recommending ART initiation regardless of
CD4 count likely only slightly enlarged the number of patients for whom ART initiation is
recommended.
Our findings are broadly consistent with those of other recent studies of ART use and viral
suppression among persons in HIV care in the U.S. An analysis from the CDC MMP found
that, among a nationwide cohort of persons, 89% were prescribed ART in the past 12
months and 71% had a VL ≤200 copies/mL.10 We found 89% ART use and 79% viral
suppression using comparable definitions. Marks and colleagues reported that 62% of
persons retained in care in six HIV outpatient clinics achieved viral suppression (<75 copies/
mL), and we found 70% viral suppression using a comparable definition.18 Programmatic
data from the In+Care Project show a mean of 69% viral suppression in reporting
populations,19 and client-level data from the Ryan White Services Report show that 85% of
clients were prescribed ART and 76% had viral suppression.20 Taken together, the
consistency of these data strongly suggest that 60-80% of persons in HIV care have viral
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suppression and stand in contrast to earlier estimates of 48-60% viral suppression among
persons in care.2, 3 In turn, the data suggest that the proportion of persons with viral
suppression among all PLWHA in the U.S. – which is based in part on estimates of viral
suppression among those in care-likely exceeds or is at the upper end of the range of
previously published estimates of 19-28%.
ART initiation will likely increase in response to current U.S. HIV/AIDS treatment
guidelines recommending ART for all PLWHA. However, half of the patients in CNICS
who had not initiated ART by the end of 2010 had a nadir CD4 count ≤500 cells/mm3, the
threshold at which initiation was uniformly recommended under treatment guidelines active
at the time. The strongest and most consistent predictor of ART non-initiation, ART
discontinuation, and failure to achieve viral suppression was a lack of engagement in
continuous HIV care. This is consistent with the findings of several previous studies21, 22
and reinforces the need to better understand barriers to sustained engagement in care.
Younger patients and patients with higher nadir CD4 counts were less likely to be engaged
in continuous HIV care. This suggests that patients’ perceived lack of need for HIV care
may be an important barrier to engagement, but may also reflect provider-related decisions
to schedule visits less frequently. Future CNICS studies will include patient-reported
measures of mental illness and current substance use to better define the impact of these
factors on care engagement and viral suppression.
Although race/ethnicity and female sex were not consistent independent predictors of lower
ART use and viral suppression, women and non-Hispanic blacks had lower rates of ART
initiation, ART continuation, and viral suppression. These disparities, particularly in the
context of disproportionate risk for HIV infection and late HIV diagnosis among non-
Hispanic blacks,23, 24 highlight the ongoing imperative to address disparities at every step in
the HIV care cascade.
The greatest strength of our study is that it provides precise contemporary information on
key steps in the HIV care cascade in the U.S. using data from a large, geographically diverse
population of persons in HIV care. CNICS data include visit dates, allowing us to directly
ascertain engagement in continuous care, and all CNICS data undergo rigorous quality
assurance procedures. However, our study was limited to patients who had ≥1 visit in 2010
and thus does not provide information about persons who are completely out of care. Indeed,
13% of the population in care in 2009 was not seen in 2010, and we do not have data on
their care and viral suppression status in 2010. The CNICS cohort is composed of patients
receiving care at university-affiliated HIV clinics that may not be representative of HIV care
throughout the U.S, but the similarity of our findings to those of MMP, which samples
patients from a diverse array of HIV clinics, suggests that this is not a major limitation. We
may have misclassified ART use by assuming continued therapy in the absence of
documented discontinuation, but such misclassification would not have affected our
estimates of virologic suppression.
In conclusion, we found that the vast majority of persons in active HIV medical care in a
nationally distributed cohort in 2010 have initiated ART and that approximately 70% have
viral suppression. Along with other recent reports, these findings suggest that viral
suppression may be more common among persons in HIV care compared with earlier
studies. Our study indicates that the increase in demand for ART under guidelines
recommending ART initiation regardless of CD4 count is likely to be relatively small and
highlights the need to work toward increasing engagement in HIV care.
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Flow diagram of study population and primary outcome measures. Shaded boxes indicate
populations described in the manuscript tables. ART, antiretroviral therapy. VL, viral load.
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Table 1
History of antiretroviral therapy (ART) initiation and continuing ART use and viral suppression at the end of
2010 among patients who received care at a CNICS clinic in 2010 (N=8633)
Percent Percent on Percent
N Ever on Continuing with viral
(% of total) ART ART suppression
Total Population 8633 (100) 94 89 70
Gender1
 Male 7170 (83) 94 90 70
 Female 1372 (16) 92* 86* 66*
 Transgender Women 79 (1) 90 89 62
 Transgender Men 12 (<1) 100 100 75
Age (years)
 18-29 750 (9) 81* 76* 56*
 30-39 1799 (21) 91* 87* 64*
 40-49 3516 (41) 95* 91* 71*
 ≥50 2568 (30) 97 93 77
Race/Ethnicity
 Non-Hispanic White 4222 (49) 94 90 73
 Non-Hispanic Black 2658 (31) 92* 86* 62*
 Hispanic 1243 (14) 95 92 74
 Asian/Pacific Islander 185 (2) 94 91 74
 American Indian 68 (1) 96 90 71
 Multiple/Other 184 (2) 92 89 79
 Missing 73 (1) 92 84 81
HIV Risk Category
 MSM 5365 (62) 94 90* 72*
 IDU (Non-MSM) 820 (10) 94 87 66
 Heterosexual 2131 (25) 93 88 66
 Other 155 (2) 96 88 66
 Missing 162 (2) 95 93 76*
Continuous Care in 2010
 Yes 7237 (84) 94 91 73
 No 1396 (16) 90* 81* 55*
NOTE. Asterisk (*) denotes p<0.05 in Pearson chi-square tests. Reference groups in each category were male gender, ≥50 years of age, Non-
Hispanic white race/ethnicity, heterosexual HIV risk category, and engaged in continuous care.
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Table 3
Factors associated with not initiating ART, discontinuing ART and having detectable viremia despite
continuing ART among patients with nadir CD4 counts ≤ 350 cells/mm3.
Variable Adjusted PR
1 of
failure to initiate ART









 Male REF REF REF
 Female 1.28 (0.60 – 2.71) 1.28 (0.91 – 1.82) 0.95 (0.83 – 1.08)
Age (years)
 18-29 1.48 (0.65 – 3.40) 2.10 (1.01–4.39) 1.46 (1.18–1.82)
 30-39 1.49 (0.70 – 3.17) 1.30 (0.82 – 2.07) 1.33 (1.07–1.64)
 40-49 1.15 (0.57 – 2.32) 1.42 (0.88 – 2.28) 1.12 (0.95 – 1.31)
 ≥50 REF REF REF
Race/Ethnicity
 Non-Hispanic White REF REF REF
 Non-Hispanic Black 1.39 (0.82 – 2.33) 1.55 (0.91 – 2.65) 1.46 (1.19–1.79)
 Hispanic 0.58 (0.30 – 1.09) 0.84 (0.91 – 2.65) 0.88 (0.65 – 1.19)
 Asian/Pacific
Islander 0.29 (0.04 – 2.12) 0.60 (0.13 – 2.72) 0.89 (0.67 – 1.19)
HIV Risk Category
 MSM 1.28 (0.53 – 3.06) 1.06 (0.73 – 1.54) 0.80 (0.62 – 1.04)
 IDU (non-MSM) 2.08 (0.98 – 4.39) 2.16 (1.29–3.60) 1.28 (0.89 – 1.86)
 Heterosexual REF REF REF
Continuous care in
2010
 Yes REF REF REF
 No 2.25 (1.34–3.78) 3.35 (2.52–4.46) 1.55 (1.26–1.89)
Years in care2 0.83 (0.75–0.93) 1.01 (0.96 – 1.07) 0.98 (0.95 – 1.02)
REF, reference group. Bold typeface signifies p-value ≤ 0.05.
1
From Poisson regression clustered by site, adjusted for all other factors in table.
2
PR is per year in care at CNICS site
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Table 4
Factors associated with not initiating ART, discontinuing ART and having detectable viremia among patients
with nadir CD4 counts 351-500 cells/mm3.
Variable Adjusted PR1 of Adjusted PR1 of ART Adjusted PR1 of
failure to initiate ART discontinuation, detectable viremia,
among patients who among patients on
initiated ART contining ART
(N=660) (N=483) (N=460)
Gender
 Male REF REF REF
 Female 1.05 (0.69 – 1.58) 1.47 (0.30 – 7.15) 0.87 (0.43 – 1.76)
Age (years)
 18-29 1.51 (0.87 – 2.63) 0.82 (0.14 – 4.67) 1.23 (0.86 – 1.77)
 30-39 1.10 (0.61 – 1.99) 1.42 (0.29 – 7.04) 1.10 (0.54 – 2.25)
 40-49 1.07 (0.68 – 1.68) 2.64 (0.93 – 7.45) 0.96 (0.52 – 1.75)
 ≥50 REF REF REF
Race/Ethnicity
 Non-Hispanic White REF REF REF
 Non-Hispanic Black 1.45 (0.23 – 1.71) 2.14 (1.06–4.31) 0.97 (0.80 – 1.17)
 Hispanic 0.99 (0.68 – 1.68) 0.85 (0.23 – 3.19) 1.07 (0.69 – 1.64)
 Asian/Pacific
Islander 1.25 (0.53 – 2.95) NC 0.68 (0.20 – 2.27)
HIV Risk Category
 MSM 1.02 (0.69 – 1.52) 1.19 (0.16 – 8.64) 0.81 (0.50 – 1.32)
 IDU (non-MSM) 1.56 (0.98 – 2.71) 1.91 (0.39 – 9.38) 1.33 (0.85 – 2.07)
 Heterosexual REF REF REF
Continuous care in
2010
 Yes REF REF REF
 No 1.79 (1.31–2.44) 2.29(1.08–4.88) 1.94 (1.08–3.48)
Years in care2 0.95 (0.88 – 1.01) 1.08 (0.97 – 1.19) 0.96 (0.88 – 1.04)
REF, reference group; NC, not calculable. Bold typeface signifies p-value ≤ 0.05.
1
From Poisson regression clustered by site, adjusted for all other factors in table
2
PR is per year in care at CNICS site
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